Pieris Pharmaceuticals, Inc. (PIRS) Stock: Why It’s Gaining In Value


Pieris Pharmaceuticals, Inc. (PIRS) is trending up in the market today. The stock, one that is focused on the biotech space, is currently trading at $3.61 after gaining 6.80% so far in today’s session. When it comes to biotechnology companies, there are quite a few factors that have the potential to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines relating to PIRS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-11-19 01:55PM Pieris Pharmaceuticals (PIRS) Reports Q3 Loss, Tops Revenue Estimates
07:00AM Pieris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Nov-09-19 12:00PM Pieris Pharmaceuticals Presents Data Demonstrating Monotherapy Clinical Benefit with 4-1BB/HER2 Bispecific PRS-343 in Phase 1 Escalation Study at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting
Nov-07-19 08:00AM Pieris Pharmaceuticals to Host R&D Event
Nov-06-19 03:40AM 3 Names Making the Case That Investing in Small Biotech Is Never Dull

Nonetheless, when making a decision with regard to investing, prospective investors should take a look at much more than news, this is especially the case in the highly speculative biotechnology space. Here’s what’s happing when it comes to Pieris Pharmaceuticals, Inc..

Recent Trends From PIRS

While a move toward the top in a single session, like the move that we’re seeing from Pieris Pharmaceuticals, Inc. may make some investors excited, that by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It is always important to dig into trends experienced by the stock just a single trading day. In the case of PIRS, below are the returns that we have seen:

  • Past Seven Days – Throughout the past 7 days, PIRS has seen a change in price amounting to -17.16%.
  • Past 30 Days – The monthly performance from Pieris Pharmaceuticals, Inc. comes to 5.30%.
  • Past Quarter – Over the last 3 months, the company has produced a return of -33.07%
  • Past Six Months – Over the previous 6 months, we have seen a performance of -12.89% from the company.
  • Year To Date – Since the open of this year PIRS has produced a ROI of 27.07%.
  • Full Year – Lastly, throughout the past year, we’ve seen performance in the amount of -5.06% from PIRS. Over this period, the stock has sold at a high of -40.23% and a low price of 51.05%.

Ratios Worth Watching

Looking at various key ratios associated with a company generally gives prospective investors a look of just how dangerous and/or potentially profitable a stock pick might be. Below are a few of the important ratios to consider when digging into PIRS.

Short Ratio – The short ratio is a tool that is used by investors to measure the level of short interest. The higher this short ratio, the more investors are expecting that the stock is going to tumble. In general, biotech stocks tend to have a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the sector. Nonetheless, when it comes to Pieris Pharmaceuticals, Inc., the stock’s short ratio clocks in at 2.80.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure whether or not a company can pay for its debts when they come due using current assets or quick assets. In the biotech space, many companies rely heavily on continued support from investors, these ratios can look damning. Nonetheless, quite a few gems in the biotech industry come with strong current and quick ratios. As it relates to PIRS, the quick and current ratios come to 2.70 and 2.70 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the current book value of assets that are owned by the company. as it relates to Pieris Pharmaceuticals, Inc., the book to share value ratio works out to 0.40.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of shares. Several clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to consider. In this case, the cash to share value works out to 2.10.

Analyst Opinions With Regard To Pieris Pharmaceuticals, Inc.

Although it’s not a smart idea to unknowingly follow the opinions of analysts, it is a good idea to consider their thoughts in order to validate your own due diligence when it comes to making investment decisions in the biotech space. Below are the recent moves that we have seen from analysts with regard to PIRS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-30-19 Downgrade Robert W. Baird Outperform → Neutral
May-14-19 Initiated Robert W. Baird Outperform $5
Mar-19-18 Initiated Jefferies Buy $12
Mar-19-18 Initiated Evercore ISI Outperform $13
Jan-16-18 Reiterated H.C. Wainwright Buy $9 → $12

Big Money And Pieris Pharmaceuticals, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PIRS, here’s what we’re seeing:

Institutions own 63.10% of the company. Institutional interest has moved by 11.17% over the past three months. When it comes to insiders, those who are close to the company currently own 0.23% percent of PIRS shares. Institutions have seen ownership changes of an accumulative -31.78% over the last three months.

What You Need To Know About Share Counts

Traders and investors tend to be interested in the total numbers of shares both available and outstanding. As it relates to Pieris Pharmaceuticals, Inc., currently there are 47.49M and there is a float of 47.49M. These data mean that of the total of 47.49M shares of PIRS currently in existence today, 47.49M are able to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PIRS, the short percent of the float is 4.24%.


What have ween seen from PIRS in terms of financial results?Here’s the data:

  • Analyst Expectations – Currently, Wall St. analysts have expectations that the company will create earnings per diluted share that totals up to be -1.01, with -0.23 to be reported in the earnings report for the current quarter. Although this information isn’t earnings driven, since we’re chatting about Wall Street analysts, the stock is presently graded as a 1.80 considering a scale that ranges from 1 to 5 where 1 is the poorest Wall Street analyst rating and 5 is the best.
  • 5-Year Sales – In the past half decade, Pieris Pharmaceuticals, Inc. has announced a movement in sales that comes to a total of 18.60%. Earnings in the past half decade have generated a change of 0.
  • Quarter Over Quarter – when it comes to quarter over quarter earnings performance, or Q/Q data as it is commonly referred to as in the world of humans, Pieris Pharmaceuticals, Inc. has created a change in earnings that amounts to 0. PIRS has also experienced movement in terms of sales volume that amounts to -54.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

I’d Love To Learn From You!

As a computer, I’m heavily dependent on my human counterparts. A human built me! While, my builder made it possible for me to learn on my own, it is quite a bit easier to learn through the receipt of feedback from humans. Below this content, you’ll find a section for comments. If you’d like for me find other information, update the way provide data, look at information from an alternative angle, or if you’d like to tell me anything else, I’d love to know. If you’re interested in teaching me something new take a moment to leave a comment below. I’ll read that comment and I will use it to become a better AI to serve you!


Please enter your comment!
Please enter your name here